User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

The effects of current subsyndromal psychiatric symptoms or past psychopathology on alcohol dependence treatment outcomes and acamprosate efficacy

Primary tabs

Mason, Barbara J. Lehert, Philippe [FUCAM]

This secondary analysis of the first U.S. acamprosate trial (N = 601) for alcohol dependence examines the effects of subsyndromal psychiatric symptoms or history of severe psychopathology on alcoholism treatment outcomes and any mitigating effects of acamprosate. Psychiatric antecedents were documented using a protocol-specific interview. Current psychiatric symptoms were assessed using Hamilton Anxiety and Depression (HAM-A, HAM-D) rating scales. Predictors of good response, defined as abstinence for ≥90% of trial duration, were identified using logistic regression. Subsyndromal anxiety (as determined by HAM-A “Anxious Mood” item) and the presence of ≥1 psychiatric antecedent were significant negative predictors of good response. Lower pretreatment drinking intensity, baseline motivation to have abstinence as a goal, and treatment with acamprosate were significant positive predictors of good response. No significant interactions among predictors were detected, indicating that they are independent, additive factors. Thus, the beneficial effects of acamprosate treatment in combination with motivational therapy may offset the liabilities for alcoholism recovery that are associated with current anxiety symptoms and/or a significant past psychiatric history.

Document type Article de périodique (Journal article)
Access type Accès restreint
Publication date 2010
Journal information "The American journal on addictions" - Vol. 19, no. 2, p. 147-154 (Mars 2010)
Peer reviewed yes
issn 1055-0496
e-issn 1521-0391
Publication status Publié
Affiliations Louvain School of Management - Operations and Information
FUCaM autre - FUCaM autre
FUCaM - Sciences de gestion
FUCaM - Sciences de gestion
Links
  1. Grant, Arch Gen Psychiatry., 61, 807 (2004)
  2. Hasin, Arch Gen Psychiatry., 64, 830 (2007)
  3. American Psychiatric Association. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders : DSM-IV (1994)
  4. Goldstein, Drugs., 66, 1229 (2006)
  5. Goetzel, J Occup Environ Med., 45, 5 (2003)
  6. Preuss, Alcohol Clin Exp Res., 26, 471 (2002)
  7. Sher, Acta Psychiatr Scand., 113, 13 (2006)
  8. Nunes, JAMA., 291, 1887 (2004)
  9. Chick, J Psychopharmacol., 17, 397 (2003)
  10. Tempesta E., ACAMPROSATE AND RELAPSE PREVENTION IN THE TREATMENT OF ALCOHOL DEPENDENCE: A PLACEBO-CONTROLLED STUDY, 10.1093/alcalc/35.2.202
  11. Morley, Addiction., 101, 1451 (2006)
  12. Durbin, Acamprosate in Relapse Prevention of Alcoholism. Proceedings of the 1st Campral Symposium, 1995, 47
  13. Rosenthal, J Addict Med., 2, 40 (2008)
  14. Mason, J Psychiatr Res., 40, 383 (2006)
  15. Mason, Brief Intervention and Medication Compliance Procedures: Therapist's Manual (1997)
  16. Williams Janet B. W., A Structured Interview Guide for the Hamilton Depression Rating Scale, 10.1001/archpsyc.1988.01800320058007
  17. Williams, Psychopharmacol Ser., 9, 48 (1990)
  18. Shear, Depress Anxiety., 13, 166 (2001)
  19. Hall, J Consult Clin Psychol., 58, 175 (1990)
  20. Sobell, Evaluating Alcohol and Drug Abuse Treatment Effectiveness: Recent Advances (1980)
  21. Anderson, J Am Stat Assoc., 52, 200 (1957)
  22. Bradizza, Clin Psychol Rev., 26, 162 (2006)
  23. Geller, Comprehensive Handbook of Drug and Alcohol Addiction, 1991, 905
  24. 24.  Mason BJ , Lehert P . Effect of acamprosate on protracted withdrawal symptoms: Anxiety, dysphoria, and insomnia. Paper presented at The 47th Annual Meeting of the College of Neuropsychopharmacology; Dec 7-11, 2008; Scottsdale, AZ.
  25. Kiefer, Neurosci Lett., 404, 103 (2006)
  26. Zalewska-Kaszubska, Neurosci Lett., 431, 221 (2008)
  27. Kotlinska, Eur J Pharmacol., 598, 57 (2008)
  28. Koob, Alcohol Clin Exp Res., 26, 586 (2002)
  29. Staner, Alcohol Clin Exp Res., 30, 1492 (2006)
  30. Hall, NIDA Res Monogr., 72, 118 (1986)
  31. 31. Motivational Enhancement Therapy Manual. NIH Publication No. 94-3723. 1994; Available at: http://pubs.niaaa.nih.gov/publications/match.htm. Accessed November 6, 2008.
  32. Bouza, Addiction., 99, 811 (2004)
  33. Mann, Alcohol Clin Exp Res., 28, 51 (2004)
Bibliographic reference Mason, Barbara J. ; Lehert, Philippe. The effects of current subsyndromal psychiatric symptoms or past psychopathology on alcohol dependence treatment outcomes and acamprosate efficacy. In: The American journal on addictions, Vol. 19, no. 2, p. 147-154 (Mars 2010)
Permanent URL http://hdl.handle.net/2078/69175